Arcutis Announces Pricing of $100 Million Public Offering
19 oct. 2023 23h45 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing...
Arcutis Announces Proposed Public Offering
19 oct. 2023 16h04 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage company focused on developing meaningful innovations...
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
13 oct. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
06 oct. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 oct. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
27 sept. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 ...
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
25 sept. 2023 09h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
19 sept. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trialsFor the primary endpoint, 25.4% of children...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 sept. 2023 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
12 sept. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United StatesIn pivotal Phase 3 trials, roflumilast cream demonstrated...